Inovio Pharmaceuticals Inc (INO)

[avav1001]

INO cancer immunotherapies used in conjunction with checkpoint inhibitors only create short-term changes of 1 to 2 months to one's immune system, since the type of DNA plasmids that INO uses is transient for the production of antigens or monoclonal Ab. A repeated electroporation is needed should one want the effect to last for more than 2 months.
For short duration of fewer than 2 months, INO bought the patent to use an inducible promoter for expression of proteins, though it's not clear that'll be needed.